Semaglutide Follow-On Peptides Face Regulatory Hurdles, Manufacturing Variability, and Clinical Comparability Demands

Type 2 diabetes mellitus (T2DM) and obesity represent significant global health challenges, with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) like semaglutide emerging as highly effective treatments. These drugs improve glycemic control, promote weight loss, and reduce cardiometabolic parameters with a low risk of hypoglycemia. While originator semaglutide is produced via recombinant DNA technology, there's growing interest in more affordable synthetic peptide versions. This transition raises critical questions about regulatory pathways, manufacturing consistency, and potential clinical implications, which this review addresses.

This narrative review synthesized existing literature on semaglutide development, global regulatory perspectives, and manufacturing variability. Researchers utilized online databases including PubMed, Scopus, and Google Scholar to identify and source relevant research articles. The review aimed to discuss the evolution of semaglutide, compare regulatory frameworks for synthetic and recombinant peptides across regions like the European Union, United States, and India, and explore how manufacturing differences might impact clinical outcomes.

The review highlights that regulatory approaches for synthetic GLP-1 peptides vary significantly across regions, with the European Union and United States employing distinct frameworks, while India adopts a risk-based approach often requiring extensive quality, safety, and clinical data. Manufacturing processes for synthetic peptides can profoundly influence critical attributes such as impurity profiles, stability, and immunogenicity, which in turn could affect patient safety and therapeutic efficacy.

The approval of follow-on versions of semaglutide necessitates a rigorous demonstration of both quality and clinical comparability with the originator product, consistent with established principles for biosimilars.

This ensures that despite different production methods, the follow-on peptides maintain equivalent clinical outcomes and safety profiles. The review underscores the expanding therapeutic potential of semaglutide beyond its current indications, further emphasizing the need for robust regulatory and manufacturing standards for any new versions.